UNSPSC 51311803: Clemizole

This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H20ClN3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T97CB3796L, chemically known as 1h-benzimidazole, 1-((4-chlorophenyl)methyl)-2-(1-pyrrolidinylmethyl)- but generally known as clemizole, which bears US NIH Compound Identifier 2782. European Medicines Agency schedules Clemizole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06650MIG.

UNSPSC 51311803 Clemizole, a Commodity code, nominally describes a specific pharmaceutical agent, but recent state and local solicitations under this code show procurement activity spanning naloxone supply, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and over-the-counter products distributed through authorized wholesalers. State and local health agencies, pharmacy benefit programs, and cooperative purchasing alliances are the primary buyers. Scope of work includes annual purchases of finished pharmaceutical units (such as 1,900 naloxone units annually from Seminole County, Florida), vendor capability assessments for direct pharmaceutical distribution channels outside traditional pharmacy benefit manager and wholesaler arrangements, and provision of generic pharmaceuticals with verified National Drug Codes through established supply-chain partners. Issuing bodies include county health departments, state health and human services commissions, and multi-state cooperative purchasing organizations; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) and the Texas Health and Human Services Commission are recent repeat participants.

Geographic activity centers on Florida and Texas, with multi-state participation coordinated through cooperative vehicles such as MMCAP covering Oregon and other member jurisdictions. Representative recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for annual naloxone and drug deactivation systems with quarterly deliveries; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026, due April 3, 2026) exploring vendor capability for direct-to-manufacturer prescription fulfillment models; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through authorized wholesalers with award effective July 1, 2026. Vendors must meet cGMP and Drug Supply Chain Security Act compliance, maintain EDI capability, and provide comprehensive insurance coverage including commercial general liability of $2,000,000 to $5,000,000 per occurrence depending on the solicitation.